Anna Liza M P de Leeuw, Jordi Giralt, Yungan Tao, Sergi Benavente, Thanh-Vân France Nguyen, Frank J P Hoebers, Ann Hoeben, Chris H J Terhaard, Lip Wai Lee, Signe Friesland, Roel J H M Steenbakkers, Lisa Tans, Jolien Heukelom, Mutamba T Kayembe, Simon R van Kranen, Harry Bartelink, Coen R N Rasch, Jan-Jakob Sonke, Olga Hamming-Vrieze
BACKGROUND AND PURPOSE: This multicenter randomized phase III trial evaluated whether locoregional control of patients with LAHNSCC could be improved by fluorodeoxyglucose-positron emission tomography (FDG-PET)-guided dose-escalation while minimizing the risk of increasing toxicity using a dose-redistribution and scheduled adaptation strategy. MATERIALS AND METHODS: Patients with T3-4-N0-3-M0 LAHNSCC were randomly assigned (1:1) to either receive a dose distribution ranging from 64-84 Gy/35 fractions with adaptation at the 10thfraction (rRT) or conventional 70 Gy/35 fractions (cRT)...
April 16, 2024: Radiotherapy and Oncology